Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Moss

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Biology of Reproduction|July 16, 2016
Identification of Beef Heifers with Superior Uterine Capacity for PregnancyThomas W Geary, Gregory W Burns, Joao G N Moraes, et al.
Science Signaling|February 27, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationEmily C Erickson, Inchul You, Grace Perry, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A Novel Whole Tissue Explant Model of Hidradenitis SuppurativaP E Leboit, D U Patel, J N Cohen, et al.
Experimental Dermatology|February 11, 2025
The Inflammatory Landscape of a Whole-Tissue Explant Model of Hidradenitis SuppurativaPhoebe E Leboit, Dhara U Patel, Jarish N Cohen, et al.
NPJ Breast Cancer|August 18, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
NPJ Breast Cancer|September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Nature Biomedical Engineering|April 8, 2024
Histopathological biomarkers for predicting the tumour accumulation of nanomedicinesJan-Niklas May, Jennifer I Moss, Florian Mueller, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Biology of Reproduction|July 16, 2016
Identification of Beef Heifers with Superior Uterine Capacity for PregnancyThomas W Geary, Gregory W Burns, Joao G N Moraes, et al.
Science Signaling|February 27, 2024
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradationEmily C Erickson, Inchul You, Grace Perry, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A Novel Whole Tissue Explant Model of Hidradenitis SuppurativaP E Leboit, D U Patel, J N Cohen, et al.
Experimental Dermatology|February 11, 2025
The Inflammatory Landscape of a Whole-Tissue Explant Model of Hidradenitis SuppurativaPhoebe E Leboit, Dhara U Patel, Jarish N Cohen, et al.
NPJ Breast Cancer|August 18, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
NPJ Breast Cancer|September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Nature Biomedical Engineering|April 8, 2024
Histopathological biomarkers for predicting the tumour accumulation of nanomedicinesJan-Niklas May, Jennifer I Moss, Florian Mueller, et al.
Pageof 6